{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T04:12:51Z","timestamp":1787026371530,"version":"build-2736575974"},"reference-count":47,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,1,13]],"date-time":"2023-01-13T00:00:00Z","timestamp":1673568000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"\n Introduction<\/jats:title>\n \n One of the challenges of personalized medicine is a departure from traditional pharmacology toward individualized, genotype-based therapies. Postmenopausal osteoporosis is a prevalent condition requiring intensive treatment, whose effects are measurable only after a long time, and the goal is bone fracture prevention. This study aimed to determine the influence of\n VDR<\/jats:italic>\n gene variation on anti-osteoporotic one-year treatment with denosumab in 63 Polish women with postmenopausal osteoporosis.\n <\/jats:p>\n <\/jats:sec>\n \n Materials and methods<\/jats:title>\n \n The correlation between bone mineral density (BMD) of the lumbar vertebral column (L1\u2013L4) and femoral neck, and genotype distributions for the\n ApaI<\/jats:italic>\n ,\n BsmI<\/jats:italic>\n ,\n FokI<\/jats:italic>\n , and\n TaqI<\/jats:italic>\n variants of the\n VDR<\/jats:italic>\n gene was analyzed. Bone fractures during denosumab therapy were also investigated.\n <\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n In the case of the\n Bsml<\/jats:italic>\n polymorphism, female patients with BB and Bb genotypes had statistically significantly higher values of BMD and T-score\/Z-score indicators, which persisted after a year of denosumab treatment. Our results indicated that the\n Bsml<\/jats:italic>\n polymorphism contributes to better bone status, and, consequently, to more efficient biological therapy. The study did not reveal significant differences between changes (delta) in BMD and genotypes for the analyzed\n VDR<\/jats:italic>\n gene\n loci<\/jats:italic>\n . In the entire study group, one bone fracture was observed in one patient throughout the yearlong period of denosumab therapy.\n <\/jats:p>\n <\/jats:sec>\n \n Conclusions<\/jats:title>\n \n BB and Bb genotypes of the\n Bsml<\/jats:italic>\n polymorphism of the\n VDR<\/jats:italic>\n gene determine higher DXA parameter values both before and after one-year denosumab therapy in postmenopausal women with osteoporosis.\n <\/jats:p>\n <\/jats:sec>","DOI":"10.3389\/fendo.2022.1063762","type":"journal-article","created":{"date-parts":[[2023,1,13]],"date-time":"2023-01-13T00:32:57Z","timestamp":1673569977000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":6,"title":["Does the VDR gene polymorphism influence the efficacy of denosumab therapy in postmenopausal osteoporosis?"],"prefix":"10.3389","volume":"13","author":[{"given":"Anna","family":"Wawrzyniak","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marzena","family":"Skrzypczak-Zieli\u0144ska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Micha\u0142","family":"Michalak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Kaczmarek-Ry\u015b","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alicja Ewa","family":"Ratajczak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna Maria","family":"Rychter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kinga","family":"Skoracka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michalina","family":"Marcinkowska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryszard","family":"S\u0142omski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agnieszka","family":"Dobrowolska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iwona","family":"Krela-Ka\u017amierczak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,1,13]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1007\/s10528-022-10197-5","article-title":"Osteoporosis and its association with vitamin d receptor, oestrogen \u03b1 receptor, parathyroid receptor and collagen type I alpha receptor gene polymorphisms with bone mineral density: A pilot study from south Indian postmenopausal women of Tamil nadu","volume":"60","author":"Fernandez","year":"2022","journal-title":"Biochem Genet"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0809493","article-title":"Denosumab for prevention of fractures in postmenopausal women with osteoporosis","volume":"361","author":"Cummings","year":"2009","journal-title":"N Engl J Med"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21218005","article-title":"Osteoporosis: From molecular mechanisms to therapies 2.0","volume":"21","author":"Tang","year":"2020","journal-title":"Int J Mol Sci"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S270829","article-title":"A review on the role of denosumab in fracture prevention","volume":"14","author":"Pang","year":"2020","journal-title":"Drug Des Devel Ther"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1080\/13697137.2018.1554643","article-title":"Association of VDR and OPG gene polymorphism with osteoporosis risk in Chinese postmenopausal women","volume":"22","author":"Wu","year":"2019","journal-title":"Climacteric"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra070553","article-title":"Vitamin d deficiency","volume":"357","author":"Holick","year":"2007","journal-title":"N Engl J Med"},{"key":"B7","article-title":"Denosumab. W","volume-title":"StatPearls","author":"Hildebrand","year":"2020"},{"key":"B8","doi-asserted-by":"publisher","first-page":"115048","DOI":"10.1016\/j.bone.2019.115048","article-title":"Off-label uses of denosumab in metabolic bone diseases","volume":"129","author":"Polyzos","year":"2019","journal-title":"Bone"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-145-4-200608150-00005","article-title":"The association between common vitamin d receptor gene variations and osteoporosis: A participant-level meta-analysis","volume":"145","author":"Uitterlinden","year":"2006","journal-title":"Ann Intern Med"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1007\/s11033-012-2072-3","article-title":"Vitamin d receptor gene polymorphisms, bone mineral density and fractures in postmenopausal women with osteoporosis","volume":"40","author":"Horst-Sikorska","year":"2013","journal-title":"Mol Biol Rep"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1210\/edrv.23.3.0464","article-title":"Genetics of osteoporosis","volume":"23","author":"Peacock","year":"2002","journal-title":"Endocr Rev"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1210\/er.2009-0044","article-title":"Genetics of osteoporosis","volume":"31","author":"Ralston","year":"2010","journal-title":"Endocr Rev"},{"key":"B13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.cca.2006.02.016","article-title":"Vitamin d receptor polymorphisms and diseases","volume":"371","author":"Valdivielso","year":"2006","journal-title":"Clin Chim Acta"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1007\/s00223-014-9840-0","article-title":"Vitamin d status and parathyroid hormone concentrations influence the skeletal response to zoledronate and denosumab","volume":"94","author":"Mosali","year":"2014","journal-title":"Calcif Tissue Int"},{"key":"B15","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.ejphar.2016.02.053","article-title":"Treatments for post-menopausal osteoporotic women, what\u2019s new? How can we manage long-term treatment","volume":"779","author":"Herrero","year":"2016","journal-title":"Eur J Pharmacol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.2147\/IJWH.S75681","article-title":"Update on denosumab in the management of postmenopausal osteoporosis: Patient preference and adherence","volume":"7","author":"Cairoli","year":"2015","journal-title":"Int J Womens Health"},{"key":"B17","first-page":"44","article-title":"DNA Isolation","volume-title":"Analysis of DNA- theory and practice","author":"S\u0142omski","year":"2011"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1007\/s00774-007-0769-5","article-title":"Association analysis of the polymorphisms of the VDR gene with bone mineral density and the occurrence of fractures","volume":"25","author":"Horst-Sikorska","year":"2007","journal-title":"J Bone Miner Metab"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2265.1997.d01-1735.x","article-title":"Vitamin d receptor gene polymorphism in men and its effect on bone density and calcium absorption","volume":"46","author":"Francis","year":"1997","journal-title":"Clin Endocrinol (Oxf)."},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1007\/s11033-011-1380-3","article-title":"Association between vitamin d receptor gene polymorphisms and bone mineral density in Chinese women","volume":"39","author":"Li","year":"2012","journal-title":"Mol Biol Rep 1 maj"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1096\/fj.06-6374fje","article-title":"Evidence for auto\/paracrine actions of vitamin d in bone: 1alpha-hydroxylase expression and activity in human bone cells","volume":"20","author":"van Driel","year":"2006","journal-title":"FASEB J"},{"key":"B22","article-title":"Correlation of vitamin d receptor gene (VDR) polymorphism with osteoporotic changes in polish postmenopausal women","volume":"30","author":"Seremak-Mrozikiewicz","year":"2009","journal-title":"Neuro Endocrinol Lett"},{"key":"B23","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1186\/s40200-014-0098-x","article-title":"Association between vitamin d receptor gene polymorphisms (Fok1 and Bsm1) and osteoporosis: A systematic review","volume":"13","author":"Mohammadi","year":"2014","journal-title":"J Diabetes Metab Disord"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1359\/jbmr.2000.15.6.1076","article-title":"The association between heel ultrasound and hormone replacement therapy is modulated by a two-locus vitamin d and estrogen receptor genotype","volume":"15","author":"Gigu\u00e8re","year":"2000","journal-title":"J Bone Miner Res"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1038\/367284a0","article-title":"Prediction of bone density from vitamin d receptor alleles","volume":"367","author":"Morrison","year":"1994","journal-title":"Nature"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1210\/jcem.84.9.5989","article-title":"Addition of alendronate to ongoing hormone replacement therapy in the treatment of osteoporosis: A randomized, controlled clinical trial","volume":"84","author":"Lindsay","year":"1999","journal-title":"J Clin Endocrinol Metab"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1093\/humrep\/15.10.2087","article-title":"Effects of alendronate and hormone replacement therapy, alone or in combination, on bone mass in postmenopausal women with osteoporosis: A prospective, randomized study","volume":"15","author":"Tira\u015f","year":"2000","journal-title":"Hum Reprod"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1210\/jcem.87.4.8323","article-title":"Effect of estrogen replacement plus low-dose alendronate treatment on bone density in surgically postmenopausal women with osteoporosis","volume":"87","author":"Palomba","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1002\/jbmr.3119","article-title":"Safety observations with 3 years of denosumab exposure: Comparison between subjects who received denosumab during the randomized FREEDOM trial and subjects who crossed over to denosumab during the FREEDOM extension","volume":"32","author":"Watts","year":"2017","journal-title":"J Bone Mineral Res"},{"key":"B30","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1002\/jbmr.1479","article-title":"Five years of denosumab exposure in women with postmenopausal osteoporosis: Results from the first two years of the FREEDOM extension","volume":"27","author":"Papapoulos","year":"2012","journal-title":"J Bone Miner Res"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9378(99)70603-4","article-title":"Association of vitamin d and estrogen receptor gene polymorphism with the effect of hormone replacement therapy on bone mineral density in Japanese women","volume":"180","author":"Kurabayashi","year":"1999","journal-title":"Am J Obstet Gynecol."},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1111\/j.1447-0756.2007.00680.x","article-title":"Effects of hormone replacement therapy on bone mineral density in Turkish patients with or without COL1A1 Sp1 binding site polymorphism","volume":"34","author":"Simsek","year":"2008","journal-title":"J Obstet Gynaecol Res"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.3390\/ijms16035452","article-title":"A polymorphism at the translation start site of the vitamin d receptor gene is associated with the response to anti-osteoporotic therapy in postmenopausal women from southern Italy","volume":"16","author":"Conti","year":"2015","journal-title":"Int J Mol Sci"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1359\/jbmr.0809010","article-title":"Comparison of the effect of denosumab and alendronate on BMD and biochemical markers of bone turnover in postmenopausal women with low bone mass: A randomized, blinded, phase 3 trial","volume":"24","author":"Brown","year":"2009","journal-title":"J Bone Miner Res"},{"key":"B35","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1359\/jbmr.090716","article-title":"Effects of denosumab on bone mineral density and bone turnover in postmenopausal women transitioning from alendronate therapy","volume":"25","author":"Kendler","year":"2010","journal-title":"J Bone Miner Res"},{"key":"B36","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.bone.2013.10.006","article-title":"Denosumab compared with risedronate in postmenopausal women suboptimally adherent to alendronate therapy: Efficacy and safety results from a randomized open-label study","volume":"58","author":"Roux","year":"2014","journal-title":"Bone"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1097\/AOG.0b013e318291718c","article-title":"Denosumab compared with ibandronate in postmenopausal women previously treated with bisphosphonate therapy: A randomized open-label trial","volume":"121","author":"Recknor","year":"2013","journal-title":"Obstet Gynecol."},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2016-1801","article-title":"Denosumab or zoledronic acid in postmenopausal women with osteoporosis previously treated with oral bisphosphonates","volume":"101","author":"Miller","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"key":"B39","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1007\/s11657-017-0351-2","article-title":"Factors associated with high 24-month persistence with denosumab: Results of a real-world, non-interventional study of women with postmenopausal osteoporosis in Germany, Austria, Greece, and Belgium","volume":"12","author":"Fahrleitner-Pammer","year":"2017","journal-title":"Arch Osteoporos"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1007\/s00223-018-0394-4","article-title":"Bone mineral density changes after 1 year of denosumab discontinuation in postmenopausal women with long-term denosumab treatment for osteoporosis","volume":"103","author":"Popp","year":"2018","journal-title":"Calcif Tissue Int"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1007\/s00223-018-0409-1","article-title":"Multiple vertebral fractures following denosumab discontinuation: Are we exaggerating","volume":"103","author":"Anastasilakis","year":"2018","journal-title":"Calcif Tissue Int"},{"key":"B42","article-title":"VDR polymorphisms effect on bone mineral density in polish postmenopausal women","volume-title":"Homo : Internationale zeitschrift fur die vergleichende forschung am menschen","author":"Ae","year":"2021"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0138606","article-title":"Lack of influence of vitamin d receptor BsmI (rs1544410) polymorphism on the rate of bone loss in a cohort of postmenopausal Spanish women affected by osteoporosis and followed for five years","volume":"10","author":"Pedrera-Canal","year":"2015","journal-title":"PloS One"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.7717\/peerj.953","article-title":"Lack of association of vitamin d receptor BsmI gene polymorphism with bone mineral density in Spanish postmenopausal women","volume":"3","author":"Moran","year":"2015","journal-title":"PeerJ"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2018.00305","article-title":"Association of vitamin d receptor gene variation with osteoporosis risk in belarusian and Lithuanian postmenopausal women","volume":"9","author":"Marozik","year":"2018","journal-title":"Front Endocrinol (Lausanne)."},{"key":"B46","doi-asserted-by":"publisher","first-page":"837","DOI":"10.3390\/nu13030837","article-title":"Vitamin d status, bone mineral density, and VDR gene polymorphism in a cohort of belarusian postmenopausal women","volume":"13","author":"Marozik","year":"2021","journal-title":"Nutrients"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.3390\/cimb43030094","article-title":"Vitamin d receptor gene variants susceptible to osteoporosis in Arab post-menopausal women","volume":"43","author":"Ansari Mohammed","year":"2021","journal-title":"Curr Issues Mol Biol"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2022.1063762\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,13]],"date-time":"2023-01-13T00:33:02Z","timestamp":1673569982000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2022.1063762\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,13]]},"references-count":47,"alternative-id":["10.3389\/fendo.2022.1063762"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2022.1063762","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,13]]},"article-number":"1063762"}}